Miguel A. Cortés González

Miguel A. Cortés González

Auto-generated profile, based on publicly available information

Miguel A. Cortés González

Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ASAnna Staniszewska
Anna Staniszewska
DPDomenic Pilger
Domenic Pilger
SGSonja J. Gill
Sonja J. Gill
KJKunzah Jamal
Kunzah Jamal
NBNatacha Bohin
Natacha Bohin
PHPetra Hamerlik
Petra Hamerlik
Purpose: We evaluated the properties and activity of AZD9574, a blood–brain barrier (BBB) penetrant selective inhibitor of PARP1, and assessed its efficacy and safety alone and in combination with temozolomide (TMZ) in preclinical models. Experimental Design: AZD9574 was interrogated in vitro for selectivity, PARylation inhibition, PARP-DNA trapping, the ability to cross the BBB, and the potential to inhibit cancer cell proliferation. In vivo efficacy was determined using subcutaneous as well as intracranial mouse xenograft models. Mouse, rat, and monkey were used to assess AZD9574 BBB penetration and rat models were used to evaluate potential hematotoxicity for AZD9574 monotherapy and the TMZ combination. Results: AZD9574 demonstrated PARP1-selectivity in fluorescence anisotropy, PARylation, and PARP-DNA trapping assays and in vivo experiments demonstrated BBB penetration. AZD9574 showed potent single agent efficacy in preclinical models with homologous recombination repair deficiency in vitro and in vivo. In an O6-methylguanine-DNA methyltransferase (MGMT)–methylated orthotopic glioma model, AZD9574 in combination with TMZ was superior in extending the survival of tumor-bearing mice compared with TMZ alone. Conclusions: The combination of three key features—PARP1 selectivity, PARP1 trapping profile, and high central nervous system penetration in a single molecule—supports the development of AZD9574 as the best-in-class PARP inhibitor for the treatment of primary and secondary brain tumors. As documented by in vitro and in vivo studies, AZD9574 shows robust anticancer efficacy as a single agent as well as in combination with TMZ. AZD9574 is currently in a phase I trial (NCT05417594). See related commentary by Lynce and Lin, p. 1217

8 December 2015 in ACS Catalysis
Verified
Journal Article
Open access
NINadia O. Ilchenko
Nadia O. Ilchenko
MCMiguel A. Cortés
Miguel A. Cortés
KSKálmán J. Szabó
Kálmán J. Szabó
The application of an air- and moisture-stable fluoroiodane reagent was investigated in the palladium-catalyzed iodofluorination reaction of alkenes. Both the iodo and fluoro substituents arise from the fluoroiodane reagent. In the case of certain palladium catalysts, the alkene substrates undergo allylic rearrangement prior to the iodofluorination process. The reaction is faster for electron-rich alkenes than for electron-deficient ones.

3 April 2018 in Chemical Communications
Verified
Journal Article
Open access
PDF file
MGMiguel A. Cortés González
Miguel A. Cortés González
PNPatrik Nordeman
Patrik Nordeman
AGAntonio Bermejo Gómez
Antonio Bermejo Gómez
DMDenise N. Meyer
Denise N. Meyer
GAGunnar Antoni
Gunnar Antoni
KSKálmán J. Szabó
Kálmán J. Szabó
An electrophilic 18F transfer reagent was synthetized by rapid, operationally simple ligand exchange from a hypervalent iodine and [18F]TBAF.

3 July 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JKJason G. Kettle
Jason G. Kettle
SBSharan K. Bagal
Sharan K. Bagal
DBDerek Barratt
Derek Barratt
MBMichael S. Bodnarchuk
Michael S. Bodnarchuk
SBScott Boyd
Scott Boyd
OSOliver Steward
Oliver Steward

30 July 2021 in Chemical Communications
Verified
Journal Article
Open access
PDF file
DMDenise N. Meyer
Denise N. Meyer
MGMiguel A. Cortés González
Miguel A. Cortés González
XJXingguo Jiang
Xingguo Jiang
LHLinus Johansson Holm
Linus Johansson Holm
MLMonireh Pourghasemi Lati
Monireh Pourghasemi Lati
KSKálmán J. Szabó
Kálmán J. Szabó
A new method for the fluorine-18 labelling of trifluoromethyl ketones has been developed. This method is based on the conversion of a–COCF3 functional group to a difluoro enol silyl ether followed by halogenation and fluorine-18 labelling. The utility of this new method was demonstrated by the synthesis of fluorine-18 labelled neutrophil elastase inhibitors, which are potentially useful for detection of inflammatory disorders.

11 October 2019 in Chemical Communications
Verified
Journal Article
Open access
PDF file
MGMiguel A. Cortés González
Miguel A. Cortés González
XJXingguo Jiang
Xingguo Jiang
PNPatrik Nordeman
Patrik Nordeman
GAGunnar Antoni
Gunnar Antoni
KSKálmán J. Szabó
Kálmán J. Szabó
α-[18F]Fluoro ethers were obtained from diazocarbonyl compounds using a hypervalent iodine based fluorine-18 reagent.